A new preclinical study evaluated the efficacy of CAR-NK cells, originating from peripheral blood IL-12/IL-18 CIML-NK cells, against a neoepitope derived from the cytosolic oncogenic nucleophosmin-1 (NPM1) mutated protein to improve the therapeutic option for the treatment of HLA-A2+ AML patients with NPM1c mutations [306]. The gene discussed is NPM1; the disease is acute myeloid leukemia.